Format

Send to

Choose Destination
Euro Surveill. 2017 Oct;22(41). doi: 10.2807/1560-7917.ES.2017.22.41.17-00645.

Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.

Author information

1
EpiConcept, Paris, France.
2
CIBER Epidemiología y Salud Pública, Institute of Health Carlos III, Madrid, Spain.
3
National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain.
4
Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain.
5
Université Paris Descartes, Sorbonne Paris Cité, APHP, CIC Cochin-Pasteur, Paris, France.
6
Inserm, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), CIC 1417, Paris, France.
7
Istituto Superiore di Sanità, Rome, Italy.
8
University of Medicine and Pharmacy Carol Davila, National Institute for Research Cantacuzino, Bucharest, Romania.
9
Department of Infectious diseases of Lithuanian University of Health Sciences, Kaunas, Lithuania.
10
Centre for Epidemiology and surveillance of infectious diseases, Centre for Infectious disease control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
11
Epidemiology Research Unit, Epidemiology Department, National Health Institute Doutor Ricardo Jorge, Lisbon, Portugal.
12
Impact Assessment Unit, National Institute for Health and Welfare, Tampere, Finland.
13
Epidemiology Service, Croatian Institute of Public Health, Zagreb, Croatia.
14
Office of the Chief Medical Officer, Budapest, Hungary.
15
Emerging Pathogens Laboratory - Fondation Mérieux, Centre International de Recherche en Infectiologie, INSERM U1111, Centre National de la Recherche Scientifique (CNRS), UMR5308, Ecole Nationale Supérieure (ENS) de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
16
Infection Control and Epidemiology Unit, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
17
National Institute for Research Cantacuzino, Bucharest, Romania, Faculty of Biology, Bucharest University.
18
Unit of Expert Microbiology, National Institute for Health and Welfare, Helsinki, Finland.
19
The members of the I-Move+ hospital working group are listed at the end of the article.

Abstract

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

KEYWORDS:

A(H3N2); Influenza; cases control; elderly; hospitalisation; vaccine effectiveness

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center